Advances in the preclinical testing of cancer therapeutic hypotheses

@article{Caponigro2011AdvancesIT,
  title={Advances in the preclinical testing of cancer therapeutic hypotheses},
  author={Giordano Michael. Caponigro and William R Sellers},
  journal={Nature Reviews Drug Discovery},
  year={2011},
  volume={10},
  pages={179-187}
}
The genetic and epigenetic underpinnings of cancer are becoming increasingly clear owing to impressive and well-coordinated ventures occurring worldwide. As our understanding of the molecular alterations driving human cancer increases, there is an opportunity to direct the clinical application of cancer therapeutics with improved accuracy. The often empirical treatment of cancer — which was initially based on inhibiting DNA synthesis and cellular division — while having led to a number of… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

References

Publications referenced by this paper.
SHOWING 1-10 OF 95 REFERENCES

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  • G Bollag
  • Nature 467,
  • 2010

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy

  • Ryan, J C.
  • J. Clin. Oncol
  • 2010

Similar Papers

Loading similar papers…